Differences in binding and effector functions between classes of TNF antagonists

Arora, Taruna; Padaki, Rupa; Liu, Ling; Hamburger, Agnes E.; Ellison, Aaron R.; Stevens, Seth R.; Louie, James S.; Kohno, Tadahiko

doi:10.1016/j.cyto.2008.11.008

Cited by 111 publications

(87 citation statements)

References 35 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Additionally, the human studies have been performed with different classes of TNF-α antagonist. It has been pointed out that the anti-TNF monoclonal antibodies (mAbs) (adalimumab and infliximab), appear more efficient than the soluble TNF receptors, thus resulting in differences in TNF-α neutralization (30,31).…”

Section: Discussionmentioning

confidence: 99%

Chronic TNF-α Neutralization Does Not Improve Insulin Resistance or Endothelial Function in “Healthy” Men with Metabolic Syndrome

Wascher

Lindeman

Sourij

et al. 2010

Mol Med

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 99%

Chronic TNF-α Neutralization Does Not Improve Insulin Resistance or Endothelial Function in “Healthy” Men with Metabolic Syndrome

Wascher

Lindeman

Sourij

et al. 2010

Mol Med

View full text Add to dashboard Cite

“…Daudi (ATCC CCL-213™) is a B lymphoblast cell line expressing the inhibitory Fcγ receptor (FcγRIIb). HEK293 cells expressing human FcγRIa, FcγRIIa, FcγRIIIa-158V, or FcγRIIIa-158F were generated as previously described [12] .…”

Section: Methodsmentioning

confidence: 99%

Function characterization of a glyco-engineered anti-EGFR monoclonal antibody cetuximab in vitro

Ruan

Wang

et al. 2014

Acta Pharmacol Sin

View full text Add to dashboard Cite

Aim: To evaluate the biochemical features and activities of a glyco-engineered form of the anti-human epidermal growth factor receptor monoclonal antibody (EGFR mAb) cetuximab in vitro. Methods: The genes encoding the Chinese hamster bisecting glycosylation enzyme (GnTIII) and anti-human EGFR mAb were cloned and coexpressed in CHO DG44 cells. The bisecting-glycosylated recombinant EGFR mAb (bisec-EGFR mAb) produced by these cells was characterized with regard to its glycan profile, antiproliferative activity, Fc receptor binding affinity and cell lysis capability. The content of galactose-α-1,3-galactose (α-Gal) in the bisec-EGFR mAb was measured using HPAEC-PAD. Results: The bisec-EGFR mAb had a higher content of bisecting N-acetylglucosamine residues. Compared to the wild type EGFR mAb, the bisec-EGFR mAb exhibited 3-fold higher cell lysis capability in the antibody-dependent cellular cytotoxicity assay, and 1.36-fold higher antiproliferative activity against the human epidermoid carcinoma line A431. Furthermore, the bisec-EGFR mAb had a higher binding affinity for human FcγRIa and FcγRIIIa-158F than the wild type EGFR mAb. Moreover, α-Gal, which was responsible for cetuximab-induced hypersensitivity reactions, was not detected in the bisec-EGFR mAb. Conclusion: The glyco-engineered EGFR mAb with more bisecting modifications and lower α-Gal content than the approved therapeutic antibody Erbitux shows improved functionality in vitro, and requires in vivo validations.

show abstract

“…However, upon addition of recombinant TNF the 2 monoclonal antibodies, but not etanercept, showed increased binding to the complement receptors 6 . Thus there are some differences between the 2 monoclonals and etanercept in terms of complement binding, induction of complement-dependent cytotoxicity, and ADCC.…”

Section: To the Editormentioning

confidence: 92%

“…In contrast, induction of complement-dependent cytotoxicity in TNF-transfected cell lines has been reported for infliximab and adalimumab but not for etanercept [3][4][5] . Further, adalimumab or infliximab induced antibody-dependent cellular cytotoxicity (ADCC) much more potently than etanercept 6 . Similarly, only the monoclonal antibodies, but not etanercept, bound complement C1q in vitro 6 .…”

Section: To the Editormentioning

confidence: 99%

See 1 more Smart Citation

Dr. N. Jacob and Dr. C.O. Jacob reply

Jacob¹,

Jacob²

2011

J Rheumatol

View full text Add to dashboard Cite

Differences in binding and effector functions between classes of TNF antagonists

Cited by 111 publications

References 35 publications

Chronic TNF-α Neutralization Does Not Improve Insulin Resistance or Endothelial Function in “Healthy” Men with Metabolic Syndrome

Chronic TNF-α Neutralization Does Not Improve Insulin Resistance or Endothelial Function in “Healthy” Men with Metabolic Syndrome

Function characterization of a glyco-engineered anti-EGFR monoclonal antibody cetuximab in vitro

Dr. N. Jacob and Dr. C.O. Jacob reply

Contact Info

Product

Resources

About